Table 2.
CD4+ CD25+ LNC of SADBE-treated AA mice display weak inhibitory potential
| cpm/1 × 105 or 1·5 × 105 cellsa (% inhibition)b | ||||
|---|---|---|---|---|
| LNC Subpopulation | Stimulus | Healthy | AA | SADBE-treated AAc |
| Unseparated | ConA | 14·244 | 9·706 | 14·009 |
| CD4+ CD25− | ConA | 10·713 | 8·180 | 11·012 |
| CD4+ CD25+ | ConA | 7·215 | 7·244 | 12·410 |
| Unseparated + CD4+ CD25+ | ConA | 7·593 (57·5) | 7·972 (40·2) | 16·189 (20·0) |
| CD4+ CD25- + CD4+ CD25+ | ConA | 7·309 (49·0) | 9·288 (21·3) | 16·389 (4·8) |
| Unseparated | anti-CD3 | 35·282 | nt | 22·680 |
| CD4+ CD25- | anti-CD3 | 31·220 | nt | 27·955 |
| CD+ CD25+ | anti-CD3 | 4·868 | nt | 22·717 |
| Unseparated + CD4+ CD25+ | anti-CD3 | 10·392 (72·4) | nt | 29·398 (13·6) |
| CD4+ CD25− + CD4+ CD25+ | anti-CD3 | 6·408 (81·0) | nt | 34·904 (11·2) |
a
Counts per minute (cpm) are derived from 1 × 105 unseparated, CD4+ CD25- and CD4+ CD25+ lymphocytes and from 1 × 105 unseparated plus 0·5 × 105 CD4+ CD25+ and 1 × 105 CD4+ CD25− plus 0·5 × 105 CD4+ CD25+ lymphocytes, respectively; s.d. of triplicates were in the range of 2–5% and are not shown for clarity of presentation.
b
% Inhibition has been calculated from the sum of cpm obtained with the individual populations.
c
Mice were treated weekly with 0·5–1% SADBE in acetone for 8–12 weeks.